|
1.
|
Yona S, Lin HH, Siu WO, Gordon S and
Stacey M: Adhesion-GPCRs: emerging roles for novel receptors.
Trends Biochem Sci. 33:491–500. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Stacey M, Chang GW, Davies JQ, et al: The
epidermal growth factor-like domains of the human EMR2 receptor
mediate cell attachment through chondroitin sulfate
glycosaminoglycans. Blood. 102:2916–2924. 2003. View Article : Google Scholar
|
|
3.
|
Yona S, Lin HH, Dri P, et al: Ligation of
the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB
J. 22:741–751. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kwakkenbos MJ, Pouwels W, Matmati M, et
al: Expression of the largest CD97 and EMR2 isoforms on leukocytes
facilitates a specific interaction with chondroitin sulfate on B
cells. J Leukoc Biol. 77:112–119. 2005.PubMed/NCBI
|
|
5.
|
Chang GW, Davies JQ, Stacey M, et al:
CD312, the human adhesion-GPCR EMR2, is differentially expressed
during differentiation, maturation, and activation of myeloid
cells. Biochem Biophy Res Commun. 353:133–138. 2007. View Article : Google Scholar
|
|
6.
|
Hamann J, Wishaupt JO, van Lier RA, Smeets
TJ, Breedveld FC and Tak PP: Expression of the activation antigen
CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis
Rheum. 42:650–658. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Matmati M, Pouwels W, van Bruggen R, et
al: The human EGF-TM7 receptor EMR3 is a marker for mature
granulocytes. J Leukoc Biol. 81:440–448. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Leemans JC, te Velde AA, Florquin S, et
al: The epidermal growth factor-seven transmembrane (EGF-TM7)
receptor CD97 is required for neutrophil migration and host
defense. J Immunol. 172:1125–1131. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
van Pel M, Hagoort H, Kwakkenbos MJ,
Hamann J and Fibbe WE: Differential role of CD97 in
interleukin-8-induced and granulocyte-colony stimulating
factor-induced hematopoietic stem and progenitor cell mobilization.
Haematologica. 93:601–604. 2008.PubMed/NCBI
|
|
10.
|
Eichler W, Hamann J and Aust G: Expression
characteristics of the human CD97 antigen. Tissue Antigens.
50:429–438. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Hamann J, Vogel B, van Schijndel GM and
van Lier RA: The seven-span transmembrane receptor CD97 has a
cellular ligand (CD55, DAF). J Exp Med. 184:1185–1189. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Hamann J, Stortelers C, Kiss-Toth E, Vogel
B, Eichler W and van Lier RA: Characterization of the CD55
(DAF)-binding site on the seven-span transmembrane receptor CD97.
Eur J Immunol. 28:1701–1707. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Qian YM, Haino M, Kelly K and Song WC:
Structural characterization of mouse CD97 and study of its specific
interaction with the murine decay-accelerating factor (DAF, CD55).
Immunology. 98:303–311. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang T, Ward Y, Tian L, et al: CD97, an
adhesion receptor on inflammatory cells, stimulates angiogenesis
through binding integrin counterreceptors on endothelial cells.
Blood. 105:2836–2844. 2005. View Article : Google Scholar
|
|
15.
|
Tchaicha JH, Reyes SB, Shin J, Hossain MG,
Lang FF and McCarty JH: Glioblastoma angiogenesis and tumor cell
invasiveness are differentially regulated by beta8 integrin. Cancer
Res. 71:6371–6381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Friedlander DR, Zagzag D, Shiff B, et al:
Migration of brain tumor cells on extracellular matrix proteins in
vitro correlates with tumor type and grade and involves alphaV and
beta1 integrins. Cancer Res. 56:1939–1947. 1996.
|
|
17.
|
Schrappe M, Klier FG, Spiro RC, Waltz TA,
Reisfeld RA and Gladson CL: Correlation of chondroitin sulfate
proteoglycan expression on proliferating brain capillary
endothelial cells with the malignant phenotype of astroglial cells.
Cancer Res. 51:4986–4993. 1991.
|
|
18.
|
Chang GW, Stacey M, Kwakkenbos MJ, Hamann
J, Gordon S and Lin HH: Proteolytic cleavage of the EMR2 receptor
requires both the extracellular stalk and the GPS motif. FEBS Lett.
547:145–150. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Qian F, Boletta A, Bhunia AK, et al:
Cleavage of polycystin-1 requires the receptor for egg jelly domain
and is disrupted by human autosomal-dominant polycystic kidney
disease 1-associated mutations. Proc Natl Acad Sci USA.
99:16981–16986. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Krasnoperov V, Lu Y, Buryanovsky L,
Neubert TA, Ichtchenko K and Petrenko AG: Post-translational
proteolytic processing of the calcium-independent receptor of
alpha-latrotoxin (CIRL), a natural chimera of the cell adhesion
protein and the G protein-coupled receptor. Role of the G
protein-coupled receptor proteolysis site (GPS) motif. J Biol Chem.
277:46518–46526. 2002. View Article : Google Scholar
|
|
21.
|
Davies JQ, Chang GW, Yona S, Gordon S,
Stacey M and Lin HH: The role of receptor oligomerization in
modulating the expression and function of leukocyte adhesion-G
protein-coupled receptors. J Biol Chem. 282:27343–27353. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Lin HH, Chang GW, Davies JQ, Stacey M,
Harris J and Gordon S: Autocatalytic cleavage of the EMR2 receptor
occurs at a conserved G protein-coupled receptor proteolytic site
motif. J Biol Chem. 279:31823–31832. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Galle J, Sittig D, Hanisch I, et al:
Individual cell-based models of tumor-environment interactions:
multiple effects of CD97 on tumor invasion. Am J Pathol.
169:1802–1811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Davies JQ, Lin HH, Stacey M, et al:
Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human
breast carcinomas and is associated with patient survival. Oncol
Rep. 25:619–627. 2011.PubMed/NCBI
|
|
25.
|
Aust G, Eichler W, Laue S, et al: CD97: a
dedifferentiation marker in human thyroid carcinomas. Cancer Res.
57:1798–1806. 1997.PubMed/NCBI
|
|
26.
|
Aust G, Steinert M, Schutz A, et al: CD97,
but not its closely related EGF-TM7 family member EMR2, is
expressed on gastric, pancreatic, and esophageal carcinomas. Am J
Clin Pathol. 118:699–707. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Liu Y, Chen L, Peng SY, Chen ZX and
Hoang-Vu C: Role of CD97(stalk) and CD55 as molecular markers for
prognosis and therapy of gastric carcinoma patients. J Zhejiang
Univ Sci B. 6:913–918. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Steinert M, Wobus M, Boltze C, et al:
Expression and regulation of CD97 in colorectal carcinoma cell
lines and tumor tissues. Am J Pathol. 161:1657–1667. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Boltze C, Schneider-Stock R, Aust G, et
al: CD97, CD95 and Fas-L clearly discriminate between chronic
pancreatitis and pancreatic ductal adenocarcinoma in perioperative
evaluation of cryocut sections. Pathology Int. 52:83–88. 2002.
View Article : Google Scholar
|
|
30.
|
Rutkowski MJ, Sughrue ME, Kane AJ, Kim JM,
Bloch O and Parsa AT: Epidermal growth factor module-containing
mucin-like receptor 2 is a newly identified adhesion G
protein-coupled receptor associated with poor overall survival and
an invasive phenotype in glioblastoma. J Neurooncol. 105:165–171.
2011. View Article : Google Scholar
|
|
31.
|
Kane AJ, Sughrue ME, Rutkowski MJ,
Phillips JJ and Parsa AT: EMR-3: a potential mediator of invasive
phenotypic variation in glioblastoma and novel therapeutic target.
Neuroreport. 21:1018–1022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Chidambaram A, Fillmore HL, Van Meter TE,
Dumur CI and Broaddus WC: Novel report of expression and function
of CD97 in malignant gliomas: correlation with Wilms tumor 1
expression and glioma cell invasiveness. J Neurosurg. 116:843–853.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ward Y, Lake R and Martin PL: et al CD97
amplifies LPA receptor signaling and promotes thyroid cancer
progression in a mouse model. Oncogene. 32:2726–2738. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Liu D, Trojanowicz B, Ye L, et al: The
invasion and metastasis promotion role of CD97 small isoform in
gastric carcinoma. PLoS One. 7:e399892012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Ward Y, Lake R, Yin JJ, et al: LPA
receptor heterodimerizes with CD97 to amplify LPA-initiated
RHO-dependent signaling and invasion in prostate cancer cells.
Cancer Res. 71:7301–7311. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Hamann J, Eichler W, Hamann D, et al:
Expression cloning and chromosomal mapping of the leukocyte
activation antigen CD97, a new seven-span transmembrane molecule of
the secretion receptor superfamily with an unusual extracellular
domain. J Immunol. 155:1942–1950. 1995.
|
|
37.
|
Gray JX, Haino M, Roth MJ, et al: CD97 is
a processed, seven-transmembrane, heterodimeric receptor associated
with inflammation. J Immunol. 157:5438–5447. 1996.PubMed/NCBI
|
|
38.
|
Rao Z, Handford P, Mayhew M, Knott V,
Brownlee GG and Stuart D: The structure of a Ca(2+)-binding
epidermal growth factor-like domain: its role in protein-protein
interactions. Cell. 82:131–141. 1995.
|
|
39.
|
D’Souza SE, Ginsberg MH and Plow EF:
Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends
Biochem Sci. 16:246–250. 1991.PubMed/NCBI
|
|
40.
|
Hamann J, Hartmann E and van Lier RA:
Structure of the human CD97 gene: exon shuffling has generated a
new type of seven-span transmembrane molecule related to the
secretin receptor superfamily. Genomics. 32:144–147. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Doolittle RF: Stein and Moore Award
address. Reconstructing history with amino acid sequences. Protein
Sci. 1:191–200. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Bjarnadottir TK, Geirardsdottir K,
Ingemansson M, Mirza MA, Fredriksson R and Schioth HB:
Identification of novel splice variants of adhesion G
protein-coupled receptors. Gene. 387:38–48. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Lin HH, Stacey M, Saxby C, et al:
Molecular analysis of the epidermal growth factor-like short
consensus repeat domain-mediated protein-protein interactions:
dissection of the CD97-CD55 complex. J Biol Chem. 276:24160–24169.
2001. View Article : Google Scholar
|
|
44.
|
Reinhardt DP, Ono RN, Notbohm H, Muller
PK, Bachinger HP and Sakai LY: Mutations in calcium-binding
epidermal growth factor modules render fibrillin-1 susceptible to
proteolysis. A potential disease-causing mechanism in Marfan
syndrome. J Biol Chem. 275:12339–12345. 2000. View Article : Google Scholar
|
|
45.
|
Jaspars LH, Vos W, Aust G, Van Lier RA and
Hamann J: Tissue distribution of the human CD97 EGF-TM7 receptor.
Tissue Antigens. 57:325–331. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Veninga H, de Groot DM, McCloskey N, et
al: CD97 antibody depletes granulocytes in mice under conditions of
acute inflammation via a Fc receptor-dependent mechanism. J Leukoc
Biol. 89:413–421. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Wang T, Tian L, Haino M, et al: Improved
antibacterial host defense and altered peripheral granulocyte
homeostasis in mice lacking the adhesion class G protein receptor
CD97. Infect Immun. 75:1144–1153. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Capasso M, Durrant LG, Stacey M, Gordon S,
Ramage J and Spendlove I: Costimulation via CD55 on human
CD4+ T cells mediated by CD97. J Immunol. 177:1070–1077.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Abbott RJ, Spendlove I, Roversi P, et al:
Structural and functional characterization of a novel T cell
receptor co-regulatory protein complex, CD97-CD55. J Biol Chem.
282:22023–22032. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Li L, Spendlove I, Morgan J and Durrant
LG: CD55 is over-expressed in the tumour environment. Br J Cancer.
84:80–86. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
MacLennan IC: Germinal centers. Annu Rev
Immunol. 12:117–139. 1994. View Article : Google Scholar
|
|
52.
|
Groeneveld PH, Erich T and Kraal G: The
differential effects of bacterial lipopolysaccharide (LPS) on
splenic non-lymphoid cells demonstrated by monoclonal antibodies.
Immunology. 58:285–290. 1986.
|
|
53.
|
Berney C, Herren S, Power CA, Gordon S,
Martinez-Pomares L and Kosco-Vilbois MH: A member of the dendritic
cell family that enters B cell follicles and stimulates primary
antibody responses identified by a mannose receptor fusion protein.
J Exp Med. 190:851–860. 1999. View Article : Google Scholar
|
|
54.
|
Kop EN, Kwakkenbos MJ, Teske GJ, et al:
Identification of the epidermal growth factor-TM7 receptor EMR2 and
its ligand dermatan sulfate in rheumatoid synovial tissue.
Arthritis Rheum. 52:442–450. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Kop EN, Adriaansen J, Smeets TJ, et al:
CD97 neutralisation increases resistance to collagen-induced
arthritis in mice. Arthritis Res Ther. 8:R1552006. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Hoek RM, de Launay D, Kop EN, et al:
Deletion of either CD55 or CD97 ameliorates arthritis in mouse
models. Arthritis Rheum. 62:1036–1042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Visser L, de Vos AF, Hamann J, et al:
Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF)
in multiple sclerosis. J Neuroimmunol. 132:156–163. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Becker S, Wandel E, Wobus M, et al:
Overexpression of CD97 in intestinal epithelial cells of transgenic
mice attenuates colitis by strengthening adherens junctions. PLoS
One. 5:e85072010. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Wong NA and Pignatelli M: Beta-catenin - a
linchpin in colorectal carcinogenesis? Am J Pathol. 160:389–401.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Rivard N: Phosphatidylinositol 3-kinase: a
key regulator in adherens junction formation and function. Front
Biosci. 14:510–522. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Mustafa T, Klonisch T, Hombach-Klonisch S,
et al: Expression of CD97 and CD55 in human medullary thyroid
carcinomas. Int J Oncol. 24:285–294. 2004.PubMed/NCBI
|
|
62.
|
Han SL, Xu C, Wu XL, Li JL, Liu Z and Zeng
QQ: The impact of expressions of CD97 and its ligand CD55 at the
invasion front on prognosis of rectal adenocarcinoma. Int J
Colorectal Dis. 25:695–702. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Wu J, Lei L, Wang S, Gu D and Zhang J:
Immunohistochemical expression and prognostic value of CD97 and its
ligand CD55 in primary gallbladder carcinoma. J Biomed Biotechnol.
2012:5876722012.PubMed/NCBI
|
|
64.
|
Mustafa T, Eckert A, Klonisch T, et al:
Expression of the epidermal growth factor seven-transmembrane
member CD97 correlates with grading and staging in human oral
squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev.
14:108–119. 2005.PubMed/NCBI
|
|
65.
|
Mikesch JH, Schier K, Roetger A, Simon R,
Buerger H and Brandt B: The expression and action of
decay-accelerating factor (CD55) in human malignancies and cancer
therapy. Cell Oncol. 28:223–232. 2006.PubMed/NCBI
|
|
66.
|
Spendlove I, Li L, Carmichael J and
Durrant LG: Decay accelerating factor (CD55): a target for cancer
vaccines? Cancer Res. 59:2282–2286. 1999.PubMed/NCBI
|
|
67.
|
Hindmarsh EJ and Marks RM:
Decay-accelerating factor is a component of subendothelial
extracellular matrix in vitro, and is augmented by activation of
endothelial protein kinase C. Eur J Immunol. 28:1052–1062. 1998.
View Article : Google Scholar
|
|
68.
|
Nasu J, Mizuno M, Uesu T, et al:
Cytokine-stimulated release of decay-accelerating factor (DAF;CD55)
from HT-29 human intestinal epithelial cells. Clin Exp Immunol.
113:379–385. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Durrant LG, Chapman MA, Buckley DJ,
Spendlove I, Robins RA and Armitage NC: Enhanced expression of the
complement regulatory protein CD55 predicts a poor prognosis in
colorectal cancer patients. Cancer Immunol Immunother. 52:638–642.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Wobus M, Vogel B, Schmucking E, Hamann J
and Aust G: N-glycosylation of CD97 within the EGF domains is
crucial for epitope accessibility in normal and malignant cells as
well as CD55 ligand binding. Int J Cancer. 112:815–822. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Safaee M, Clark AJ, Oh MC, et al:
Overexpression of CD97 confers an invasive phenotype in
glioblastoma cells and is associated with decreased survival of
glioblastoma patients. PLoS One. 8:e627652013. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Bates RC, DeLeo MJ III and Mercurio AM:
The epithelial-mesenchymal transition of colon carcinoma involves
expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res.
299:315–324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Xie K: Interleukin-8 and human cancer
biology. Cytokine Growth Factor Rev. 12:375–391. 2001. View Article : Google Scholar
|
|
74.
|
Wobus M, Huber O, Hamann J and Aust G:
CD97 overexpression in tumor cells at the invasion front in
colorectal cancer (CC) is independently regulated of the canonical
Wnt pathway. Mol Carcinog. 45:881–886. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Xu Y, Gaudette DC, Boynton JD, et al:
Characterization of an ovarian cancer activating factor in ascites
from ovarian cancer patients. Clin Cancer Res. 1:1223–1232.
1995.PubMed/NCBI
|
|
76.
|
Guo R, Kasbohm EA, Arora P, et al:
Expression and function of lysophosphatidic acid LPA1 receptor in
prostate cancer cells. Endocrinology. 147:4883–4892. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Kitayama J, Shida D, Sako A, et al:
Over-expression of lysophosphatidic acid receptor-2 in human
invasive ductal carcinoma. Breast Cancer Res. 6:R640–R646. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Park JW, Zarnegar R, Kanauchi H, et al:
Troglitazone, the peroxi-some proliferator-activated receptor-gamma
agonist, induces antiproliferation and redifferentiation in human
thyroid cancer cell lines. Thyroid. 15:222–231. 2005. View Article : Google Scholar
|
